Research status and development of humanized anti-tumor antibody drugs.
- Author:
Yuan HE
1
;
Juan ZHANG
;
Zhi-ke LI
;
Min WANG
Author Information
1. China Pharmaceutical University & Peking Union Medical College, Nanjing, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antibodies, Monoclonal, Humanized;
immunology;
therapeutic use;
Antineoplastic Agents;
immunology;
therapeutic use;
Humans;
Neoplasms;
therapy
- From:
Acta Pharmaceutica Sinica
2012;47(10):1269-1274
- CountryChina
- Language:Chinese
-
Abstract:
With the development of therapeutic monoclonal antibodies, the therapeutic antibodies have increasingly dominated the global pharmacy market in recent years, which are concentrated on the treatment of carcinoma, transplant rejection, auto-immune diseases etc. Meanwhile, the therapeutic antibodies could be categorized on the humanized proportion into several different types, such as murine-derived antibody, chimeric antibody, humanized antibody and human antibody. Herein, we focused both on antibody research hot spots and humanized anti-tumor antibody drugs. Moreover, in accordance with the classical examples of humanized anti-tumor antibody drugs approved by relevant authorities worldwide, we explained the research status and situation from both the humanized technologies and production of humanized antibodies. Additionally, it seemingly rational and reasonable to demonstrate the trend of further humanized anti-tumor antibody drugs in the prospect of the present situation either domestic or overseas.
